Background: The antiretroviral therapy (ART) has changed the profile of the HIV disease, shifting its category from what is recognized as terminal illness to chronic diseases associated with increased cardiovascular disorders risk. Several studies have indicated that chromium (Cr3+) plays an important role in maintaining the normal levels of blood glucose, reducing plasma cholesterol and triglycerides concentration, inhibiting oxidative stress and modulating inflammatory cytokines response. Objective: This study aims to evaluate the effects of chromium supplementation in biomarkers - such as inflammatory response, glucose and lipid metabolism - of HIV-associated lipodystrophy patients. Methodology: A randomized, double-blind and placebo-controlled clinical trial will be undertaken with fifty (n=50) ART-experienced and HIV-associated lipodystrophy patients. Patients will be randomly assigned to receive 1 of 2 treatments, which consisted of a daily oral supplement with (C) or without (P) the inclusion of 200¼g of chromium for 3 consecutive months. During the supplementation period, all patients will be inquired and submitted for evaluation as following: clinical (history and physical exams), nutritional (diet surveys and body composition) and biochemistry (complete blood count, protein total/fractions, glucose/lipid profile, liver enzymes, urea/creatinine, inflammatory markers and blood/urine analysis for chromium content).
News published in Agência FAPESP Newsletter about the scholarship: